Driven by Biopharmaceutical Innovations and Gene Therapies, the market Booms Amidst Growing Incidence of Hemophilia and Von Willebrand Disease ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...

STA Pharmaceutical Hong Kong Investment, the shareholder of WUXI XDC (02268.HK), placed 37.8 million shares of the company at $30.855-31.515 per share, a discount of 4.5-6.5% to last Friday's ...

Meanwhile, WuXi Vaccines, a subsidiary of WuXi Biologics, says it will sell a vaccine facility in Dundalk, Ireland, to the US drugmaker Merck & Co. for $521 million. WuXi Biologics says the sale ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co. for approximately USD 500 million. The decision comes ahead of potential U.S ...

(Borrell, 1/7) Reuters: China's WuXi Biologics To Sell Irish Vaccine Facility To Merck As US Curbs Loom China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S.

WuXi Biologics (HKEX: 2269), today announced a definitive agreement with Merck & Co’s (NYSE: MRK) MSD International GmbH unit, whereby the latter will acquire WuXi Vaccines’ facility in Dundalk, ...

Dr. Michael Har-Noy, Founder and Chief Medical Officer of Mirror Biologics stated: "We are pleased to enter into this clinical collaboration with Merck KGaA, Darmstadt, Germany, evaluating the ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral ... Although the newsthat WuXi Bio sold its Ireland vaccine facility to Merck (MRK) for about $500M sent the stock lower ...